Facrbook
Follow @eaonc
Youtube
  • Home
  • About Us
    • Organizational Overview
    • Executive Leadership
    • Governance
    • Our Members
    • Scientific Planning and Review
    • Trial Monitoring
    • Operations
    • Biostatistics and Data Management
    • Collaborations
    • Active Clinical Trials
    • Find a Participating Institution
    • Scientific Achievements
    • Constitution
  • Scientific Programs
    • Cancer Control and Outcomes Program
    • Therapeutic Studies Program
    • Biomarker Sciences Program
  • Research Support
    • Research Support Committees
    • Mentoring Program
    • Training and Education
  • Research Cores
    • Central Biorepository and Pathology Facility
    • Imaging Core Laboratory
    • Leukemia Translational Science Center
    • Thoracic Malignancies Integrated Translational Science Center
  • Resources
    • Active Clinical Trials: Resources
    • Group Meetings
    • Comis Translational Science Symposium
    • NCI-MATCH / EAY131 for Researchers
    • Publications
    • ECOG Performance Status
    • ECOG-ACRIN Sample Tracking System
    • CIRB
    • Medidata Rave®
    • TRIAD™
    • SOAPP
    • PrECOG
    • Related Websites
    • Document Library
  • Patients
    • Myths and Facts
    • External Resources and Links
    • Active Clinical Trials: Resources
  • News and Info
    • Advocacy Blog
    • Member Blog
    • Press Releases
  • Contact Us
    • Donations
    • Locations
    • Office of Communications
    • Find a Participating Institution
    • Principal Investigators
Follow @eaonc

Biomarker Sciences Program

Deputy Chair, Biomarker Sciences Program
Keith T. Flaherty, MD
Harvard University, the Dana-Farber/Harvard Cancer Center, and the Massachusetts General Hospital Cancer Center
Biography
Email

Program Description

Within its novel Biomarker Sciences Program, the ECOG-ACRIN Cancer Research Group evaluates and integrates cross-cutting biologic opportunities, explicitly recognizing the importance of scientific discovery in the development of new cancer therapies. This program provides unprecedented opportunities for the incorporation of novel predictive (integral) and response (integrated) biomarkers into our therapeutic trials. It is anticipated that the development of biomarker-focused, small trials will facilitate more efficient design of definitive trials, requiring fewer patients to demonstrate larger treatment effects and patient selection being based on the presence of biomarkers predictive of clinical response.

The Biomarker Science Program is leading the precision medicine cancer trial, NCI-MATCH / EAY131.

History of ECOG-ACRIN’s Biomarker Science Program

The ECOG-ACRIN Biomarker Sciences Program was established in 2011 to provide the Group with a uniquely coordinated multidisciplinary translational science resource composed of some of the world’s leaders. The program promotes the parallel development of biologically driven therapy and associated imaging- and laboratory-based biomarkers. The Biomarker Sciences Program is an excellent venue to promote the interests of member cancer centers and SPOREs (Specialized Programs of Research Excellence), ensuring involvement by their basic and translational scientists. ECOG-ACRIN also invites experts in genetic, RNA, miRNA, and protein-based assay development and leaders in imaging to participate in the program, regardless of their membership status in the Group.

Biomarker Sciences Committees

The program contains four scientific committees, which interface with the scientific committees of the Therapeutic Studies Program, which covers 11 cancer types. These committees also interface with the scientific committees of the Cancer Control and Outcomes Program on the development of biomarkers for chemo-prevention agents and the study of the biology of symptoms and symptom management.

  • Biomarker Steering Committee
  • Developmental Therapeutics Committee
  • Imaging Committee
  • Laboratory Science and Pathology Committee

The program is complemented by the Group’s Research Cores, a network of tissue and specimen banks, imaging archive, and translational science programs.

 

28
Scientific Programs
Cancer Control and Outcomes Program
Therapeutic Studies Program
Biomarker Sciences Program
  • Biomarker Steering Committee
  • Developmental Therapeutics Committee
  • Imaging Committee
  • Laboratory Science and Pathology Committee

ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

© 2012-2020 ECOG-ACRIN Cancer Research Group. All rights reserved.  |  Disclaimer